BR112012012766A2 - controlled release galantamine pharmaceutical compositions - Google Patents

controlled release galantamine pharmaceutical compositions

Info

Publication number
BR112012012766A2
BR112012012766A2 BR112012012766A BR112012012766A BR112012012766A2 BR 112012012766 A2 BR112012012766 A2 BR 112012012766A2 BR 112012012766 A BR112012012766 A BR 112012012766A BR 112012012766 A BR112012012766 A BR 112012012766A BR 112012012766 A2 BR112012012766 A2 BR 112012012766A2
Authority
BR
Brazil
Prior art keywords
galantamine
pharmaceutical compositions
controlled release
release
absence
Prior art date
Application number
BR112012012766A
Other languages
Portuguese (pt)
Inventor
Ashok Omray
Harish Tulsidutt Bhatt
Sandhya Rajendra Shenoy
Original Assignee
Usv Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Usv Ltd filed Critical Usv Ltd
Publication of BR112012012766A2 publication Critical patent/BR112012012766A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

composições farmacêuticas de galantamina de liberação controlada. a presente invenção divulga composições farmacêuticas de liberação controlada de galantamina compreendendo uma pluralidade de minicomprimidos matricais compreendendo galantamina ou sal farmaceuticamente aceitável da mesma e pelo menos um agente modificador de liberação. as referidas composições caracterizam-se pela ausência de revestimento modificador da taxa de libaração e/ou pela ausência de uma porção de liberação imediata da galantamina.controlled release galantamine pharmaceutical compositions. The present invention discloses controlled release pharmaceutical compositions of galantamine comprising a plurality of matrix mini-tablets comprising galantamine or pharmaceutically acceptable salt thereof and at least one release modifying agent. said compositions are characterized by the absence of a release rate modifying coating and / or the absence of an immediate release portion of galantamine.

BR112012012766A 2009-11-26 2010-11-26 controlled release galantamine pharmaceutical compositions BR112012012766A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2736MU2009 2009-11-26
PCT/IN2010/000767 WO2011064797A2 (en) 2009-11-26 2010-11-26 Controlled release pharmaceutical compositions of galantamine

Publications (1)

Publication Number Publication Date
BR112012012766A2 true BR112012012766A2 (en) 2016-09-06

Family

ID=44067021

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012012766A BR112012012766A2 (en) 2009-11-26 2010-11-26 controlled release galantamine pharmaceutical compositions

Country Status (4)

Country Link
EP (1) EP2503996A2 (en)
BR (1) BR112012012766A2 (en)
CA (1) CA2781826A1 (en)
WO (1) WO2011064797A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1007767B (en) * 2011-07-26 2012-11-19 Φαρματεν Αβεε, Prolonged release pharmaceutical composition comprising galantamine and method for the preparation thereof.
US10105320B2 (en) * 2013-10-03 2018-10-23 Altria Client Services Soluble fiber lozenge
BG67408B1 (en) * 2019-04-12 2022-01-17 Софарма Ад Oral drug composition with plant alkaloid for treatment of addictions
CN113384536B (en) * 2020-03-14 2024-04-02 鲁南制药集团股份有限公司 Sustained release galanthamine pamoate particles for injection and preparation method thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
CA1326632C (en) 1988-10-26 1994-02-01 Bonnie Davis Long-active drug formulations comprising galanthamine for treatment of alzheimer's disease
DK1140105T3 (en) 1998-12-24 2004-02-23 Janssen Pharmaceutica Nv Controlled release galantamine preparation
US20040097484A1 (en) 2002-11-14 2004-05-20 Marc Cantillion Once a day galantamine pharmaceutical compositions and methods of use
WO2005048979A2 (en) 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
WO2009024858A1 (en) * 2007-08-22 2009-02-26 Aurobindo Pharma Limited Controlled release dosage form of galantamine
EP2190419A1 (en) * 2007-10-05 2010-06-02 KRKA, D.D., Novo Mesto Multi particulate matrix system containing galantamine
EP2044933A1 (en) * 2007-10-05 2009-04-08 KRKA, D.D., Novo Mesto Multi particulate matrix system containing galantamine
EP2116232B1 (en) * 2008-05-09 2012-02-15 Ratiopharm GmbH Medicine containing galanthamine with controlled release

Also Published As

Publication number Publication date
WO2011064797A2 (en) 2011-06-03
CA2781826A1 (en) 2011-06-03
WO2011064797A3 (en) 2012-04-12
EP2503996A2 (en) 2012-10-03

Similar Documents

Publication Publication Date Title
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
ECSP10010042A (en) COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY
BR112013008601A8 (en) CLEVIDIPINE EMULSION FORMULATIONS CONTAINING ANTIMICROBIAL AGENTS
BR112015010977A2 (en) pyridine derivative, pharmaceutically acceptable salt thereof or solvate thereof, prodrug, pharmaceutical composition, urat1 inhibitor, agent for treating or preventing one or more diseases, and, compound
DOP2007000053A (en) TETRAHYDROPIRIDOTIENOPIRIMIDINA COMPOUNDS AND METHODS FOR USE
MX2020005078A (en) Novel cytoprotective drugs.
UY33350A (en) PROCEDURE FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS INTENDED FOR ADMINISTRATION BY ORAL ROUTE THAT INCLUDE ONE OR SEVERAL ACTIVE PRINCIPLES AND THE COMPOSITIONS THAT UNDERSTAND THEM
BR112017028140A2 (en) pharmaceutical formulations
PH12015501783A1 (en) Pharmaceutical compositions for the treatment of helicobacter pylori
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
CO2017007076A2 (en) Indenyl compounds, pharmaceutical compositions and medical uses thereof
EP3231436A4 (en) Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient
BR112015023481A2 (en) controlled release liposome drug composition
BR112012012766A2 (en) controlled release galantamine pharmaceutical compositions
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
BR112012024428A2 (en) fast dissolving pharmaceutical composition
BR112015025058A8 (en) MATRIX TYPE PHARMACEUTICAL COMPOSITION CONTAINING LACOSAMIDE
WO2011014003A3 (en) (+)-3-hydroxymorphinan derivatives as neuroprotectants
PH12016500693A1 (en) Slow-release solid oral compositions
PH12018501758A1 (en) Oritavancin formulations
BR112012024346A2 (en) therapeutic agent or prophylactic agent for alzheimer's disease
HK1163526A1 (en) A medicament for treating schizophrenia comprising cilostazol
BR112013009647A2 (en) vitamin derivative, pharmaceutical composition, therapeutic agent, and compound
WO2014119984A3 (en) Pharmaceutical composition comprising a biphasic immediate-release system for controlling convulsive seizures and pain
BR112018070521A2 (en) process for preparing solid mesalazine formulations

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired